Abstract:
Extremely High Frequency (EHF) distributed antenna systems and related components and methods are disclosed. In one embodiment, a base unit for distributing EHF modulated data signals to a RAU(s) is provided. The base unit includes a downlink data source input configured to receive downlink electrical data signal(s) from a data source. The base unit also includes an E-O converter configured to convert downlink electrical data signal(s) into downlink optical data signal(s). The base unit also includes an oscillator configured to generate an electrical carrier signal at a center frequency in the EHF band. The base unit also includes a modulator configured to combine the downlink optical data signal(s) with the electrical carrier signal to form downlink modulated optical signal(s) comprising a downlink optical data signal(s) modulated at the center frequency of the electrical carrier signal. The modulator is further configured to send the downlink modulated optical signal to the RAU(s).
Abstract:
The present invention provides a method for accurately determining the likelihood that a subject will respond to treatment with an immunomodulatory composition comprising detecting homozygosity for HLA-C2 alleles or at least two markers one of which is a marker for an HLA-C allele and one of which is a marker for an IL28B allele, and processes for selecting suitable subjects for therapy or for continued therapy, and for providing appropriate therapy to subjects, based on the assay results.
Abstract:
The invention relates to agents for the treatment of hepatitis C virus infection. More specifically, the invention relates to antagonists of cannabinoid type 1 receptor signalling pathway proteins and their use for the treatment of hepatitis C virus infection.
Abstract:
The invention relates to agents for the treatment of hepatitis C virus infection. More specifically, the invention relates to antagonists of cannabinoid type 1 receptor signalling pathway proteins and their use for the treatment of hepatitis C virus infection.
Abstract:
The present invention is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis. The invention thus provides pharmaceutical compositions comprising specific anti-eotaxin 2 antibodies for use alone or in combination with other therapeutic agents in the treatment of inflammatory, autoimmune and cardiovascular diseases. The invention also provides specific anti-eotaxin-2 monoclonal antibodies, and methods of treatment utilizing the antibodies of the invention.
Abstract:
Methods and apparatus for drying ceramic green bodies include providing one or more ceramic green bodies in a microwave heating chamber operatively connected to a microwave source and a PLC. The total mass of the ceramic green bodies present in the microwave heating chamber is determined. Microwave energy is generated with the microwave source and transmitted from the microwave source to the microwave heating chamber. A transmitted power of the microwave energy transmitted from the microwave source to the microwave heating chamber is measured with power sensors. The reflected power of reflected microwave energy reflected back from the microwave heating chamber is also measured. The power of the microwave energy transmitted from the microwave source to the microwave heating chamber is adjusted based on the total mass of ceramic green bodies present in the microwave heating chamber, the measured transmitted power and the measured reflected power.
Abstract:
Disclosed are methods for reducing the extent of myocardial ischemia/reperfusion injury, comprising administering to a human prior to reperfusion of the ischemic myocardium or pre-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof. Methods of treating ischemia/reperfusion injury, comprising administering to a human after reperfusion of the ischemic myocardium or post-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof are also disclosed.
Abstract:
A microwave applicator assembly (100) includes a microwave applicator (102) that excites TE modes and provides a generally circular heating pattern in a lossy dielectric material. The microwave applicator has a processing chamber bounded by a circumferential wall (110) in which a plurality of indents (102) are formed. The microwave applicator assembly (100) may further include a feed waveguide (120) coupled to the microwave applicator (102) for inputting microwaves into the processing chamber. The microwave applicator assembly (100) may further include one or more choking sections in communication with the processing chamber (104) to enhance heating efficiency and reduce microwave leakage.
Abstract:
A radio-over-fiber (RoF) hybrid wired/wireless transponder is disclosed that is configured to provide both wireless and wired communication between a hybrid head-end and one or more client devices. The hybrid transponder includes optical-to-electrical (O/E) and electrical-to-optical (E/O) conversion capability and is configured to frequency multiplex/demultiplex electrical "wired" signals and electrical "wireless" signals. The electrical wireless signals are wirelessly communicated to the client device(s) via a multiple- input/multiple-output (MIMO) antenna system within a cellular coverage area. The electrical wired signals are communicated to the client device(s) via a wireline cable that plugs into a wireline cable port on the transponder. The hybrid RoF system includes a hybrid head-end capable of transmitting and receiving wired and wireless optical signals, and an optical fiber cable that is optically coupled to the hybrid head-end and to at least one hybrid transponder. Drop-down transponder configurations that allow for easy wired and wireless connectivity between the client device(s) to the transponder(s) are also disclosed.
Abstract:
The radio-over-fiber (RoF) transponder includes a converter unit adapted to convert RF electrical signals into optical signals and vice versa, and an antenna system electrically coupled to the converter unit. The antenna system includes first and second Z-shaped patch antenna elements formed on an antenna substrate. These patches are adapted to respectively transmit and receive radio-frequency (RF) electromagnetic radiation at a first frequency fA (e.g., 2.4 GHz) over a first picocell. The antenna system also includes a square patch antenna element formed atop the antenna substrate surface between the first and second Z-shaped patch antenna elements. The square patch antenna is adapted to transmit and receive RF electromagnetic radiation at a second frequency fB (e.g., 5.2 GHz) over a second picocell substantially co-located with the first picocell. One or more spaced-apart transponders can be supported by one or more optical fibers to form an array of picocells.